H.C. Wainwright analyst Edward White lowered the firm’s price target on Inhibikase Therapeutics to $5 from $15 and keeps a Buy rating on the shares. The firm cites dilution from the capital raise for the target cut. Topline data from the 201 trial of risvodetinib in Parkinson’s is expected next month, the analyst tells investors in a research note. H.C. Wainwright anticipates a 2027 launch for risvodetinib in Parkinson’s disease with sales of $7M that year and sales of $336M in 2030.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKT:
- Inhibikase Therapeutics Secures $110M for Drug Development
- Inhibikase Therapeutics prices 58.3M shares at $1.37 in private placement
- Inhibikase Therapeutics Unveils PAH and Parkinson’s Drug Pipeline
- Inhibikase Therapeutics reports Q2 EPS (66c), consensus (67c)
- IKT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue